GeneMedicine Inc. breathed a sigh of relief as it not only successfully maintained its cancer gene therapy agreement with F. Hoffmann-La Roche Ltd., but expanded both the scope and length of what may have been a make or break deal for the company.

GMED (The Woodlands, Texas) and Roche (Basel, Switzerland) now will exclusively work with each other to develop non-viral gene therapy GeneMedicines involving interleukin-2 (IL-2), interferon-alpha (IFN-alpha) and interleukin-12 (IL-12) to treat all human cancers.